New York: The single-shot Johnson & Johnson Covid-19 vaccine produces a strong response against the Delta variant of the virus, the company has said.
Data showed that the durability of immune response for recipients of its vaccine lasted at least eight months, the healthcare company said, adding that its vaccine was 85 per cent effective and could also help prevent hospitalisation and death.
“Current data for the eight months studied so far shows that the single-shot Johnson & Johnson Covid-19 vaccine generates a strong neutralising antibody response that does not wane; rather, we observe an improvement over time,” Mathai Mammen, head of research & development at J&J’s drugs business, said in the statement.
The company said the single-dose vaccine was 85% effective against severe or critical disease and demonstrated protection against hospitalization and death.
The shot neutralized the delta variant within 29 days of a first dose, and protection matured and improved over time.
First identified in India, Delta is becoming the globally dominant variant of the coronavirus, according to the World Health Organization.
